glp 1 and dual glp 1 gip receptor agonists GLP-1-based therapies for type 2 diabetes: from single, triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Effects, working principles and target

Most patients experience no adverse effects, and when present, theyre typically mild and transient including temporary digestive changes as the gut adjusts, minor nausea (usually resolving within days), or altered bowel patterns during initial therapy

Tirzepatide is a once-weekly injectable, dual glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist

& Clarke, J

Acta 1763 , 542548 (2006)

Science of the Total Environment, 801: 149709 Mandal A, Sinha C, Jena A K, Ghosh S, Samanta A (2010)

Consistent with these beneficial effects being mediated through adipose tissue, lipodystrophic mice with severely depleted adiposity, or mice with adipose-specific deletion of FGFR1 have blunted glycemic responses to FGF21 (240, 241)